All In Biotech

Drug Trial Radar · NCT00823628

Contrast-medium Induced Nephrotoxicity in Patients Undergoing Coronary Angiography - Iodixanol Versus Iopromide

Comparison of Contrast-medium Induced Nephrotoxicity Between Iodixanol and Iopromide in Patients With Renal Insufficiency Undergoing Coronary Angiography

Last checked: Nov 19, 2026Latest source record: Jul 7, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 420 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

420

Planned (sponsor's estimate)

Start

Feb 2009

Primary completion

May 2010

Study completion Jun 2010

Sponsor

Lead sponsor
Seoul National University Bundang HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 15, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In the treatment of coronary heart disease which is the major cause of heart attack, direct mechanical treatment with catheters such as the coronary angiography, coronary balloon intervention and stenting intervention are the mainstay of therapy in recent years. In that procedures, the investigators should use the contrast media, and it may cause kidney toxicity especially in the patients with underlying kidney disease and decreased kidney function. The investigators intended to find out which contrast agent has less kidney toxicity in the catheter based treatment of coronary arterial diseases in patients with underlying decreased kidney function

Conditions

  • Chronic Renal Insufficiency
  • Coronary Angiography

Interventions

  • contrast agent (iopromide)Drug

    coronary angiography using the allocated contrast agent

  • contrast agent (iodixanol)Drug

    coronary angiography using the allocated contrast agent

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of contrast induced nephropathy, defined as either a relative increase in serum creatinine from baseline of >=25% or an absolute increase of >=0.5mg/dL(44.2µmol/L)Time frame: days 1 and 2

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cardiovascular Center, Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.